title: Efficacy of proveblue (methylene blue) in an experimental cerebral malaria murine model.
abstract: Although 100% of untreated mice infected with Plasmodium berghei died with specific signs of cerebral malaria and 100% of mice treated with 3 mg/kg dihydroartemisinin, the active metabolite of artesunate, which is used as the first-line treatment for severe malaria, also died but showed no specific signs of cerebral malaria, 78% of mice treated with 10 mg/kg Proveblue (methylene blue) and 78% of mice treated with a combination of 3 mg dihydroartemisinin and 10 mg/kg Proveblue survived and showed no specific signs of cerebral malaria or detectable parasites.
authors.affiliation: Unité de Parasitologie, Département d'Infectiologie de Terrain, Institut de Recherche Biomédicale des Armées, Marseille, France.
authors.forename: Jérome
authors.initials: J
authors.lastname: Dormoi
authors.forename: Sébastien
authors.initials: S
authors.lastname: Briolant
authors.forename: Camille
authors.initials: C
authors.lastname: Desgrouas
authors.forename: Bruno
authors.initials: B
authors.lastname: Pradines
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D016779:Malaria, Cerebral / Q000188:drug therapy*; D008751:Methylene Blue / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D010962:Plasmodium berghei / Q000187:drug effects*
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004791:Enzyme Inhibitors; C039060:artenimol; D008751:Methylene Blue